Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Cell Death Dis ; 6: e1850, 2015 Aug 06.
Article in English | MEDLINE | ID: mdl-26247735

ABSTRACT

Tyrosine kinase inhibitors (TKIs) have shown strong activity against non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. However, a fraction of EGFR wild-type (WT) patients may have an improvement in terms of response rate and progression-free survival when treated with erlotinib, suggesting that factors other than EGFR mutation may lead to TKI sensitivity. However, at present, no sufficiently robust clinical or biological parameters have been defined to identify WT-EGFR patients with greater chances of response. Therapeutics validation has necessarily to focus on lung cancer stem cells (LCSCs) as they are more difficult to eradicate and represent the tumor-maintaining cell population. Here, we investigated erlotinib response of lung CSCs with WT-EGFR and identified EGFR phosphorylation at tyrosine1068 (EGFRtyr1068) as a powerful biomarker associated with erlotinib sensitivity both in vitro and in preclinical CSC-generated xenografts. In contrast to the preferential cytotoxicity of chemotherapy against the more differentiated cells, in EGFRtyr1068 cells, erlotinib was even more active against the LCSCs compared with their differentiated counterpart, acquiring potential value as CSC-directed therapeutics in the context of WT-EGFR lung cancer. Although tumor growth was inhibited to a similar extent during erlotinib or chemotherapy administration to responsive tumors, erlotinib proved superior to chemotherapy in terms of higher tolerability and reduced tumor aggressiveness after treatment suspension, substantiating the possibility of preferential LCSC targeting, both in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) tumors. We conclude that EGFRtyr1068 may represent a potential candidate biomarker predicting erlotinib response at CSC-level in EGFR-WT lung cancer patients. Finally, besides its invariable association with erlotinib sensitivity in EGFR-WT lung CSCs, EGFRtyr1068 was associated with EGFR-sensitizing mutations in cell lines and patient tumors, with relevant diagnostic, clinical and therapeutic implications.


Subject(s)
Antineoplastic Agents/pharmacology , ErbB Receptors/genetics , Erlotinib Hydrochloride/pharmacology , Gene Expression Regulation, Neoplastic , Neoplastic Stem Cells/drug effects , Protein Kinase Inhibitors/pharmacology , Adenocarcinoma/drug therapy , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Aged , Animals , Apoptosis/drug effects , Biomarkers, Pharmacological/metabolism , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Drug Evaluation, Preclinical , ErbB Receptors/metabolism , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Male , Mice , Mice, SCID , Middle Aged , Neoplasm Staging , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Phosphorylation/drug effects , Proto-Oncogene Proteins p21(ras)/genetics , Proto-Oncogene Proteins p21(ras)/metabolism , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , Signal Transduction , Tyrosine/metabolism , Xenograft Model Antitumor Assays
2.
Cephalalgia ; 35(1): 45-50, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25053749

ABSTRACT

PURPOSE: The purpose of this article is to investigate the efficacy and safety of frovatriptan plus dexketoprofen 25 or 37.5 mg (FroDex25 or FroDex37.5, respectively) compared to that of frovatriptan 2.5 mg (Frova) in menstrually related migraine (MRM). AIM: The aim of this article is to analyze a subgroup of 76 women who treated an MRM attack in this multicenter, randomized, double-blind, parallel-group study. METHODS: The primary end-point was the proportion of patients who were pain free (PF) at two hours. Secondary end-points included pain-relief (PR) at two hours and 48 hours sustained pain free (SPF). RESULTS: PF rates at two hours were 29% under Frova, 48% under FroDex25 and 64% under FroDex37.5 (p < 0.05). PR at two hours was Frova 52%, FroDex25 81% and FroDex37.5 88%, while 48 hours SPF was 18% under Frova, 30% under FroDex25 and 44% under FroDex37.5. CONCLUSION: Combining frovatriptan+dexketoprofen produced higher PF rates at two hours compared to Frova while maintaining efficacy at 48 hours. Tolerability profiles were comparable.


Subject(s)
Analgesics/administration & dosage , Menstruation Disturbances/drug therapy , Migraine Disorders/drug therapy , Adult , Analgesics/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Carbazoles/administration & dosage , Carbazoles/adverse effects , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Menstruation Disturbances/complications , Migraine Disorders/etiology , Serotonin Receptor Agonists/administration & dosage , Serotonin Receptor Agonists/adverse effects , Tryptamines/administration & dosage , Tryptamines/adverse effects
3.
Cell Death Differ ; 21(12): 1877-88, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25034785

ABSTRACT

Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC, which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic avenue in NSCLC.


Subject(s)
Antineoplastic Agents/pharmacology , Biphenyl Compounds/pharmacology , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/pathology , Neoplastic Stem Cells/physiology , Nitrophenols/pharmacology , Sulfonamides/pharmacology , bcl-X Protein/antagonists & inhibitors , Animals , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/metabolism , Cell Line, Tumor , Cell Proliferation , Cell Survival/drug effects , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Mice, Inbred NOD , Mice, SCID , Neoplastic Stem Cells/drug effects , Piperazines/pharmacology , Tumor Burden , Xenograft Model Antitumor Assays , bcl-X Protein/metabolism
4.
Neurol Sci ; 32 Suppl 1: S149-51, 2011 May.
Article in English | MEDLINE | ID: mdl-21533733

ABSTRACT

The aim of the present study was to investigate the impact of comorbid migraine on quality of life (QoL) of patients with multiple sclerosis (MS). Forty-four MS patients with comorbid migraine and 44 sex/age-matched MS subjects free from primary headache were evaluated. Although we observed that comorbid migraine did not affect the physical and mental composite scores of the MS QoL-54 questionnaire, MS patients with migraine had worse scores than those without in role limitation due to physical problems (RL-P) (p = 0.035), bodily pain (BP) (p = 0.030) and health perception (HP) (p = 0.023) subscales. These findings were confirmed by multivariate regression analyses adjusted for demographic, clinical and psychometric variables. Significant correlations between MIDAS score and RL-P (r = -0.43, p = 0.003), BP (r = -0.51; p < 0.001), and HP (r = -0.38; p = 0.01) were also found. In conclusion, we suggest that investigating and treating migraine in MS patients might contribute to improve their QoL.


Subject(s)
Migraine Disorders/epidemiology , Multiple Sclerosis, Relapsing-Remitting/epidemiology , Quality of Life , Adult , Comorbidity , Disability Evaluation , Female , Humans , Male , Migraine Disorders/psychology , Multiple Sclerosis, Relapsing-Remitting/psychology , Surveys and Questionnaires
5.
Cell Death Differ ; 15(3): 504-14, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18049477

ABSTRACT

Lung carcinoma is often incurable and remains the leading cancer killer in both men and women. Recent evidence indicates that tumors contain a small population of cancer stem cells that are responsible for tumor maintenance and spreading. The identification of the tumorigenic population that sustains lung cancer may contribute significantly to the development of effective therapies. Here, we found that the tumorigenic cells in small cell and non-small cell lung cancer are a rare population of undifferentiated cells expressing CD133, an antigen present in the cell membrane of normal and cancer-primitive cells of the hematopoietic, neural, endothelial and epithelial lineages. Lung cancer CD133(+) cells were able to grow indefinitely as tumor spheres in serum-free medium containing epidermal growth factor and basic fibroblast growth factor. The injection of 10(4) lung cancer CD133(+) cells in immunocompromised mice readily generated tumor xenografts phenotypically identical to the original tumor. Upon differentiation, lung cancer CD133(+) cells acquired the specific lineage markers, while loosing the tumorigenic potential together with CD133 expression. Thus, lung cancer contains a rare population of CD133(+) cancer stem-like cells able to self-renew and generates an unlimited progeny of non-tumorigenic cells. Molecular and functional characterization of such a tumorigenic population may provide valuable information to be exploited in the clinical setting.


Subject(s)
Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/pathology , Lung Neoplasms/pathology , Neoplastic Stem Cells/pathology , AC133 Antigen , Animals , Antigens, CD/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Small Cell/metabolism , Cell Differentiation , Drug Resistance, Neoplasm , Female , Glycoproteins/metabolism , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Mice , Mice, SCID , Neoplastic Stem Cells/metabolism , Peptides/metabolism , Phenotype , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
6.
Regul Pept ; 143(1-3): 69-75, 2007 Oct 04.
Article in English | MEDLINE | ID: mdl-17477982

ABSTRACT

Corticotropin-releasing factor (CRF) induces the dilatation of cerebral blood vessels and increases cerebral blood flow (CBF). CRF receptor antagonists reduce ischaemic damage in the rat. In the present study, the expression of CRF around cerebral vessels has been investigated in the rat. No CRF immunoreactivity was identified around pial or intracerebral vessels in the absence of cerebral ischaemia. Four hours after middle cerebral artery occlusion (MCAo), intensely CRF-positive blood vessels were evident on the ischaemic cortical surface and in the peri-infarct and infarct zone. Increased CRF immunoreactivity was also detected in swollen axons in subcortical white matter, caudate nucleus and lateral olfactory tract of the ipsilateral hemisphere, consistent with the failure of axonal transport. These data provide morphologic support for a role of CRF in the pathophysiology of cerebral ischaemia.


Subject(s)
Brain Ischemia/metabolism , Cerebral Infarction/metabolism , Corticotropin-Releasing Hormone/metabolism , Animals , Brain Ischemia/pathology , Brain Ischemia/physiopathology , Cerebral Infarction/pathology , Cerebral Infarction/physiopathology , Cerebrovascular Circulation , Corticotropin-Releasing Hormone/physiology , Immunohistochemistry , Male , Middle Cerebral Artery/chemistry , Middle Cerebral Artery/pathology , Rats , Rats, Inbred F344 , Receptors, Corticotropin-Releasing Hormone/physiology , Time Factors
8.
J Neurol Sci ; 173(1): 10-7, 2000 Feb 01.
Article in English | MEDLINE | ID: mdl-10675574

ABSTRACT

In order to evaluate the clinical usefulness of emergency computed tomography (CT) in acute ischemic stroke, we assessed whether CT findings within the first few hours of stroke onset reliably predict type, site and size of the index infarction, and risk of death or disability. For this reason we reviewed clinical and CT findings in a cohort of unselected consecutive patients referred to the stroke unit of a large urban hospital because of a presumed ischemic stroke in the anterior circulation (AC), and submitted to CT within 5 h from onset. Out of 158 total patients, emergency CT revealed parenchymal changes compatible with AC focal ischemia in 77 (49%) and a hyperdense middle cerebral artery (MCA) in 41 (26%). Parenchymal changes and hyperdense MCA predicted an AC territorial infarction respectively in 97% of cases (95% C.I. 93% to 100%) and in 95% of cases (95% C.I. 88% to 100%). Site and size of early changes coincided with those of final lesions in 79% of patients with cortical changes and in 95% of patients with cortico-subcortical changes, but only in 37% of patients with initial subcortical changes, the remainder of whom developed a cortico-subcortical infarction. At logistic regression parenchymal changes were the only independent predictor of an AC territorial infarction. Negative predictive power, however, was only 40% (95% C. I. 29% to 51%) for parenchymal changes, and 35% for hyperdense MCA (95% C.I. 26% to 44%). The odds for death or disability at 1 month associated with parenchymal changes were thrice as high as with negative CT, even after adjustment for clinical severity on admission. These results indicate that CT scan adds significantly to the prediction of outcome made on clinical grounds. The frequent development of a territorial infarction in patients with initially negative CT and the subsequent recruitment of the cortex in those initially exhibiting only subcortical changes suggest that the transition from ischemia to infarction often occurs after the first five h following stroke.


Subject(s)
Hypoxia-Ischemia, Brain/diagnostic imaging , Stroke/diagnostic imaging , Adult , Aged , Aged, 80 and over , Brain/diagnostic imaging , Brain/physiopathology , Female , Humans , Male , Middle Aged , Middle Cerebral Artery/diagnostic imaging , Middle Cerebral Artery/physiopathology , Prognosis , Time Factors , Tomography, X-Ray Computed
9.
Neurology ; 53(8): 1876-9, 1999 Nov 10.
Article in English | MEDLINE | ID: mdl-10563647

ABSTRACT

The CSF level of the isoprostane 8-epi-prostaglandin (PG)-F2alpha (a reliable marker of oxidative stress in vivo) was three times higher in subjects with definite MS than in a benchmark group of subjects with other neurologic diseases. This increase was not correlated with that of PGE2 levels, measured as an index of cyclooxygenase activity, and was much lower in steroid-treated patients. The levels of 8-epi-PGF2alpha were moderately correlated with the degree of disability.


Subject(s)
Dinoprost/analogs & derivatives , Multiple Sclerosis/metabolism , Oxidative Stress , Adult , Aged , Dinoprost/cerebrospinal fluid , Dinoprostone/cerebrospinal fluid , Disabled Persons , F2-Isoprostanes , Female , Humans , Male , Middle Aged , Multiple Sclerosis/cerebrospinal fluid , Multiple Sclerosis/physiopathology , Osmolar Concentration , Prostaglandin-Endoperoxide Synthases/metabolism , Reference Values
10.
Acta Neurochir Suppl ; 73: 73-80, 1999.
Article in English | MEDLINE | ID: mdl-10494345

ABSTRACT

The growing body of clinical and instrumental information that can be gathered from the earliest phases of stroke has radically modified the way in which neurologists tackle the treatment of stroke patients. It is now theoretically possible to tailor therapeutic choices on the basis of prognostic estimates made within a few hours of stroke onset, that is at a time when numerous options to limit the ischemic insult are still open. However, once many hours or even days have passed, all one can do is witness the effects of a natural course which by then is virtually unmodifiable. This applies not only to stroke patients being treated within the context of pharmacological trials, but also to those in daily clinical management, since some choices, such as when and how to treat brain oedema and give thrombolytics, may now be made earlier and more accurately than in the past. Emergency CT in particular discloses important indices of subsequent clinical evolution and outcome, thus adding to already well-known predictors such as age and severity of neurological status at hospital admission [20]. CT does have the aforementioned limitations regarding inter-observer agreement, which may, however, be minimised by an appropriate training of observers. Moreover it has intrinsic limitations regarding the visualisation of the actual brain tissue damage, since up to one fifth of patients with no or very limited early CT signs may present symptomatic hemorrhagic transformation after thrombolysis [23] and approximately one sixth of early deteriorating patients do not show early CT signs [52]. Other techniques, such as positron and single photon emission tomography and in particular MR imaging, which may shed light on tissue viability and perfusion as well as arterial patency simultaneously, might be able to provide more accurate information [19] Nevertheless, CT is still the most widely used tool in clinical centres which hospitalise stroke patients, and is unlikely to be routinely replaced by the other imaging devices in the foreseeable future. Consequently, there is an urgent need both for a general consensus on the identification criteria of early CT signs and for the widest possible awareness of knowledge regarding CT capabilities among neurologists [47], waiting for the wide applicability of newer technologies.


Subject(s)
Brain/physiopathology , Cerebrovascular Disorders/physiopathology , Tissue Survival , Cerebrovascular Disorders/diagnosis , Cerebrovascular Disorders/diagnostic imaging , Cerebrovascular Disorders/therapy , Humans , Tomography, X-Ray Computed
11.
Stroke ; 28(3): 632-7; discussion 637-8, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9056623

ABSTRACT

BACKGROUND AND PURPOSE: Because in humans the clinical benefits of reperfusion remain controversial, it is important to determine whether reperfusion per se reduces infarct volume. In the nonhuman primate, mostly semiquantitative assessments of infarction have been performed. When ischemic volumes have been calculated, it has been for the acute or subacute stages of experimental stroke and may thus not adequately reflect the total volume of consolidated infarction. METHODS: Anesthetized baboons were subjected to 6 hours of either reversible or permanent middle cerebral artery occlusion (MCAO). Approximately 4 weeks later, the brains were processed for neuropathological examination to allow assessment of the final infarct volume determined by the difference of healthy tissue between occluded and nonoccluded hemispheres. RESULTS: Reversible MCAO resulted in a small essentially subcortical infarction (mean+/-SD, 0.58+/-0.31 cm3) in 6 of 10 baboons: the infarct (pannecrosis) was restricted to the head of the caudate nucleus, internal capsule, and putamen; 4 of 10 baboons showed no evidence of macroscopic infarction. Permanent MCAO produced a larger subcortical infarct in all 7 baboons studied (2.37+/-1.32 cm3; P=.0006 by Wilcoxon-Mann-Whitney test); the lesion was more extensive and encompassed the external capsule and, in 2 baboons, the adjacent insular cortex. CONCLUSIONS: We conclude that under optimal experimental conditions, an ischemic episode of 6 hours in duration is well tolerated in the anesthetized adolescent baboon, with 4 animals showing no signs of macroscopic brain damage. Thus, early reestablishment of cerebral blood flow after a focal ischemic insult is not detrimental but indeed is beneficial in terms of the final infarct volume (both at the subcortical and cortical levels) produced by occlusion of a major cerebral artery. The data further suggest a feasible time window in which to initiate and continue therapeutic interventions.


Subject(s)
Arterial Occlusive Diseases/physiopathology , Brain Ischemia/physiopathology , Cerebral Infarction/pathology , Reperfusion Injury/physiopathology , Anesthesia , Animals , Arterial Occlusive Diseases/complications , Arterial Occlusive Diseases/pathology , Brain Ischemia/pathology , Cerebral Infarction/physiopathology , Cerebrovascular Disorders/pathology , Cerebrovascular Disorders/physiopathology , Cohort Studies , Hemiplegia/etiology , Hemiplegia/physiopathology , Hydrogen-Ion Concentration , Necrosis , Papio , Reperfusion Injury/pathology
12.
Stroke ; 28(1): 10-4, 1997 Jan.
Article in English | MEDLINE | ID: mdl-8996480

ABSTRACT

BACKGROUND AND PURPOSE: Our aims were to identify predictors of early neurological improvement in acute ischemic stroke patients, to evaluate its impact on clinical outcome, and to investigate possible mechanisms. METHODS: A consecutive series of 152 first-ever ischemic hemispheric stroke patients hospitalized within 5 hours of onset underwent a first CT scan within 1 hour of hospitalization, and the initial subset of 80 patients also underwent angiography. During the first 48 hours of hospital stay, an increase or a decrease of 1 or more points in the admission Canadian Neurological Scale (CNS) score was defined as early improvement or early deterioration, respectively. Repeated CT scan or autopsy was performed 5 to 9 days after stroke. RESULTS: Thirty-four patients (22%) improved, 84 (56%) remained stable, and 34 (22%) deteriorated. Logistic regression, which took into account vascular risk factors, baseline clinical and CT data, and therapies administered, selected younger age, lower admission CNS score, and absence of early hypodensity at first CT as independent predictors of early improvement. Among the patients who underwent angiography, logistic regression selected arterial patency and presence of collateral blood supply as independent predictors of early improvement. At the repeated CT scan or autopsy, improving patients presented the highest frequency of small infarcts. Thirty-day case-fatality rate and disability were lower in improving patients. Variables independently associated with outcome at logistic regression were admission CNS score, early deterioration, and early improvement. CONCLUSIONS: Early improvement can be predicted by the absence of early CT hypodensity and is highly predictive of good outcome. Presence of collateral blood supply and presumably early spontaneous recanalization are likely to be the mechanisms underlying early improvement.


Subject(s)
Brain Ischemia/therapy , Aged , Analysis of Variance , Brain Ischemia/diagnostic imaging , Brain Ischemia/physiopathology , Cerebral Angiography , Cerebral Infarction/diagnostic imaging , Cerebral Infarction/physiopathology , Disease Progression , Female , Humans , Male , Middle Aged , Odds Ratio , Regression Analysis , Reproducibility of Results , Risk Factors , Tomography, X-Ray Computed , Treatment Outcome
13.
J Cereb Blood Flow Metab ; 16(6): 1176-88, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8898690

ABSTRACT

Studies in humans suggest that regions that show maximal increases in brain oxygen extraction fraction (OEF) in the hours following an ischemic episode are those most vulnerable for infarction and are often, although not always, associated with the final site of infarction. To clarify this issue, we followed the hemodynamic and metabolic characteristics of regions with an initially maximally increased OEF and compared them with the ultimately infarcted region in an experimental stroke model. Positron emission tomography (PET) was used to obtain functional images of the brain prior to and following reversible unilateral middle cerebral artery occlusion (MCAO) in 11 anesthetized baboons. To model early reperfusion, the clips were removed 6 h after occlusion. Successive measurements of regional CBF (rCBF), regional CMRO2 (rCMRO2), regional cerebral blood volume, and regional OEF (rOEF) were performed during the acute (up to 2 days) and chronic (> 15 days) stage. Late magnetic resonance imaging (MRI) scans (co-registered with PET) were obtained to identify infarction. Reversible MCAO produced an MRI-measurable infarction in 6 of 11 baboons; the others had no evidence of ischemic damage. Histological analysis confirmed the results of the MRI investigation but failed to show any evidence of cortical ischemic damage. The lesion was restricted to the head of the caudate nucleus, internal capsule, and putamen. The infarct volume obtained was 0.58 +/- 0.31 cm3. The infarcts were situated in the deep MCA territory, while the area of initially maximally increased OEF was within the cortical mantle. The mean absolute rCBF value in the infarct region of interest (ROI) was not significantly lower than in the highest-OEF ROI until 1-2 days post-MCAO. Cerebral metabolism in the deep MCA territory was always significantly lower than that of the cortical mantle; decreases in CMRO2 in the former region were evident as early as 1 h post-MCAO. In the cortical mantle, the rOEF was initially significantly higher than in the infarct-to-be zone. Subsequently, the OEF declined in both regions. The differences in the time course of changes in CMRO2 and OEF between these two regions, with the eventually infarcted area showing earlier metabolic degradation and in turn decline in OEF, presumably underlie their different final outcomes. In conclusion, following MCAO, the region that shows an early maximal increase in the OEF is both topographically and physiologically distinct from the region with final consolidated infarction if reperfusion is allowed at 6 h. This high OEF, although indicative of a threatened condition, is not an indicator of inescapable consolidated infarction and is thus a situation in which therapy could be envisaged. Whether or not it is at risk of infarction and thus constitutes one target for therapy remains to be seen.


Subject(s)
Cerebral Arteries/pathology , Cerebral Infarction/metabolism , Oxygen/metabolism , Animals , Cerebral Arteries/physiopathology , Cerebral Infarction/pathology , Cerebral Infarction/physiopathology , Oxygen Consumption , Papio , Regional Blood Flow , Tomography, Emission-Computed
14.
Stroke ; 27(8): 1306-9, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8711792

ABSTRACT

BACKGROUND AND PURPOSE: Ischemic stroke patients whose initial clinical presentation suggests an involvement of the anterior circulation (AC) are sometimes found to have a posterior circulation (PC) infarct, a fact that may generate erroneous decisions in clinical management. We investigated the prevalence of this misdiagnosis in the first few hours after stroke onset. METHODS: We performed a cohort study of 158 patients hospitalized within 5 hours of onset of a presumed AC ischemic stroke, as diagnosed on clinical grounds. RESULTS: Final CT or pathology diagnosis was AC infarct in 128 patients (81%), a repeatedly negative CT in 14 (9%), PC infarct (5 pons, 1 midbrain and cerebellum, 6 supratentorial territory of the posterior cerebral artery) in 12 (8%), and other or undiagnosed lesions in 4 (3%). AC and PC stroke patients did not differ in terms of age, vascular risk factors, and initial severity, but the latter were more frequently men (83% versus 53%; P = .04), were hospitalized later (mean +/- SD, 168 +/- 86 versus 109 +/- 55 minutes; P = .001), and presented a pure motor hemiparesis or a sensorimotor stroke (50% versus 33%) more often than their counterparts. At baseline CT, PC stroke patients never exhibited an early parenchymal hypodensity in the carotid territory or a hyperdense middle cerebral artery, which were instead found in 59% (P = .0003) and 31% (P = .02) of AC stroke patients, respectively. Early neurological deterioration, 1 month case-fatality rate, and disablement in survivors were comparable in the two groups. CONCLUSIONS: Shortly after onset the clinical discrimination between AC and nontypical PC infarcts is not reliable, which explains the frequent occurrence of this misdiagnosis. Emergency CT scan helps in the differential diagnosis only when it demonstrates an early focal hypodensity within the carotid territory.


Subject(s)
Brain Ischemia/diagnosis , Cerebral Infarction/diagnosis , Cerebrovascular Circulation/physiology , Cerebrovascular Disorders/diagnosis , Acute Disease , Aged , Brain Ischemia/mortality , Brain Ischemia/physiopathology , Cerebral Infarction/mortality , Cerebral Infarction/physiopathology , Cerebrovascular Disorders/mortality , Cerebrovascular Disorders/physiopathology , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Risk Factors , Tomography, X-Ray Computed
15.
Neurology ; 46(2): 341-5, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8614491

ABSTRACT

OBJECTIVE: To identify, in the first 5 hours of acute brain infarct, clinical and radiologic predictors of subsequent hemorrhagic transformation (HT), and to evaluate its influence on the clinical course. BACKGROUND: The identification of early predictors of HT might be important to plan antithrombotic or thrombolytic treatments. PATIENTS: One hundred fifty consecutive patients with cerebral anterior circulation infarct systematically underwent a first CT within 5 hours of onset. During the first week after stroke, we performed a repeat CT or autopsy to look for HT. Outcome measures were early neurologic deterioration within the first week of onset and 30-day case fatality rate and disability. RESULTS: HT was observed in 65 patients (43%): 58 (89%) had a petechial HT and seven (11%) a hematoma. Among initial clinical an CT findings, the only independent predictor of HT was early focal hypodensity. Its presence was associated with subsequent HT in 77% of cases (95% CI, 68 to 86%), whereas its absence predicted the absence of subsequent HT in 94% of cases (95% CI, 89 to 99%). No baseline clinical or CT characteristic differentiated patients with petechial HT from those with hematoma. Antithrombotic and antiplatelet agents did not influence the occurrence of either type of HT. The frequency of early neurologic deterioration and of 30-day death or disability in HT patients was twice as high as in those without HT. However, a large-sized infarct and the presence of mass effect at the repeat CT or autopsy were the only factors independently linked to both the outcome events, irrespective of the development of HT. Clinical evolution of HT patients given antithrombotics was comparable with that of HT patients not receiving these drugs. CONCLUSIONS: HT of a brain infarct is a common event that occurs independently of anticoagulation and can be reliably predicted as early as 5 hours from stroke onset by the presence of focal hypodensity at CT. Apart from the infrequent cases of massive hematoma, HT does not influence prognosis, whereas a poor outcome in HT patients is correlated with a higher frequency of large edematous infarcts in this subgroup. The clinical course and final outcome of HT in anticoagulated patients does not differ from that of non-anticoagulated HT patients.


Subject(s)
Cerebral Hemorrhage/physiopathology , Cerebral Infarction/drug therapy , Cerebral Infarction/physiopathology , Cerebrovascular Disorders/drug therapy , Cerebrovascular Disorders/physiopathology , Fibrinolytic Agents/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Aged , Cerebral Hemorrhage/epidemiology , Cerebral Hemorrhage/prevention & control , Cerebral Infarction/diagnostic imaging , Cerebrovascular Disorders/diagnostic imaging , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Risk Factors , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
16.
Arch Neurol ; 52(3): 250-5, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7872877

ABSTRACT

OBJECTIVE: To develop a model for predicting outcome in the first few hours after the onset of an ischemic stroke on the basis of the clinical findings obtained during a rapid bedside examination. DESIGN: Clinical records were retrieved from the data bank of a randomized multicenter trial. The resulting case series was split into two subgroups that served as a "training set" and a "test set." Logistic regression was applied to the training set to select the prognostic predictors among baseline clinical findings. The performances of the model based on independent prognostic predictors were then validated in the test set. SETTING: Eleven primary care institutions (either hospitals or university clinics) participating in the Italian Acute Stroke Study on the efficacy of hemodilution and monosialoganglioside in acute ischemic stroke. PATIENTS: Consecutive noncomatose patients (N = 300) observed within the first 6 hours after the onset of a first supratentorial ischemic stroke. MAIN OUTCOME MEASURE: Death or disablement 4 months after the index stroke. Disablement was defined as a score of 3 or higher on the Rankin Scale. RESULTS: Age and CNS score defined six risk groups with a predicted 4-month poor outcome rate ranging from 10% (patients aged 70 years or younger and with an initial CNS score of 7 or higher) to 89% (patients older than 70 years and with a CNS score of 4.5 or lower). When a risk of poor outcome of 60% was taken as a cutoff, the accuracy of the prediction was 78% +/- 6% in the training set and 72% +/- 9% in the test set. CONCLUSION: Long-term outcome can be predicted in the first few hours following an acute ischemic stroke by means of a simple model based on age and CNS score.


Subject(s)
Cerebrovascular Disorders/etiology , Ischemic Attack, Transient/complications , Acute Disease , Aged , Cerebrovascular Disorders/physiopathology , Female , Forecasting , Humans , Ischemic Attack, Transient/physiopathology , Male , Multicenter Studies as Topic , Nervous System/physiopathology , Prognosis , Randomized Controlled Trials as Topic
17.
Cephalalgia ; 14(5): 374-5, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7828198

ABSTRACT

We describe the case report of a migraine sufferer who developed ergotamine-induced headache and subsequently replaced ergotamine with daily sumatriptan (100 mg p.o.). The features of the headache were unchanged except for the presence of superimposed migraine-like headaches that occurred every 24 h.


Subject(s)
Ergotamine/adverse effects , Headache/chemically induced , Headache/drug therapy , Sumatriptan/therapeutic use , Adult , Ergotamine/therapeutic use , Female , Humans , Sumatriptan/administration & dosage
18.
Stroke ; 24(12): 2046-57; discussion 2057-8, 1993 Dec.
Article in English | MEDLINE | ID: mdl-8248987

ABSTRACT

BACKGROUND AND PURPOSE: Recent reports have shown an increase in specific binding (in vitro) of [3H]PK 11195 to peripheral-type benzodiazepine receptors in both experimental animals and humans, reflecting a glial/macrophagic reaction within and around focal ischemic insults. We have evaluated by positron emission tomography the time course of changes in brain uptake in vivo of 11C-labeled PK 11195 and flumazenil (an antagonist of central benzodiazepine receptors) as indirect and direct markers of neuronal loss, respectively, after focal cerebral ischemia. METHODS: Ten anesthetized baboons were submitted to sequential positron emission tomography studies between day 1 and day 91 after unilateral middle cerebral artery occlusion. The studies consisted of successive assessments, in the same positron emission tomography session, of [11C]PK 11195, [11C]flumazenil, cerebral blood flow, and oxygen consumption; late computed tomographic scans were obtained to map the approximate contours of infarction and to define a concentric peri-infarct area. RESULTS: We found a significant time-dependent increase in [11C]PK 11195 uptake in the peri-infarcted area, maximum at 20 to 40 days after occlusion. In contrast, there was a time- and perfusion-independent significant decrease in [11C]flumazenil uptake in the infarcted area, stable from day 2 onward, and already present in one baboon at day 1. Challenge studies with saturating doses of cold ligands confirmed that these changes represented alterations in specific binding. [11C]Flumazenil uptake was not affected in hypometabolic (but apparently noninfarcted, ie, deafferented) cortical areas. CONCLUSIONS: The delayed and apparently transient increases in [11C]PK 11195 specific uptake in vivo presumably represent glial/macrophage reaction; the marked depression in [11C]flumazenil specific binding, which appears selective for synaptic damage, is both precocious and sustained and thus may be better suited for the early assessment of ischemic damage in humans.


Subject(s)
Brain Ischemia/metabolism , Cerebral Infarction/metabolism , Receptors, GABA-A/metabolism , Animals , Brain Ischemia/physiopathology , Brain Mapping , Cerebral Infarction/physiopathology , Flumazenil/metabolism , Isoquinolines/metabolism , Macrophages/metabolism , Magnetic Resonance Imaging , Male , Neuroglia/metabolism , Neurons/metabolism , Oxygen Consumption , Papio , Regional Blood Flow , Time Factors , Tomography, Emission-Computed , Tomography, X-Ray Computed
19.
Arch Neurol ; 49(10): 1013-20, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1417508

ABSTRACT

Using high-resolution positron emission tomography and the oxygen 15 continuous inhalation method, we examined the changes in cerebral metabolic rate of oxygen, blood flow, blood volume, and oxygen extraction fraction as a function of age in 25 optimally healthy, unmedicated volunteers who ranged in age from 20 to 68 years. Subjects were strictly selected for absence of cerebrovascular risk factors, dementia, or mental disorders; they had neither biological nor clinical abnormalities, and no focal anomaly on computed tomographic scan. Regions of interest were determined according to the anatomical structures defined on corresponding computed tomographic scan cuts obtained using a stereotaxic head-positioning method. This same method was also used for positron emission tomographic imaging. There was no significant effect of aging on PaCO2 values, hematocrit, arterial blood pressure, cholesterol and triglyceride levels, and blood glucose levels. In most cerebral cortex gyri, the cerebral metabolic rate of oxygen significantly decreased with age according to a linear pattern, with the same magnitude (about -6% per decade) in all four lobes and on both sides. This effect of age on cortical cerebral metabolic rate of oxygen persisted when the possible influence of cortical atrophy, gender, and head size were partialled out. In contrast, the white matter, deep gray nuclei, thalamus, and cerebellum were not significantly affected. The cerebral blood volume declined with a similar pattern to cerebral metabolic rate of oxygen, while changes in cerebral blood flow were less significant, presumably because of larger variance of data across subjects.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Aging/physiology , Blood Volume , Brain/physiology , Cerebrovascular Circulation , Oxygen Consumption , Adult , Aged , Aging/metabolism , Brain/diagnostic imaging , Female , Humans , Male , Middle Aged , Radionuclide Imaging
20.
Brain ; 115 ( Pt 3): 795-807, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1628203

ABSTRACT

Positron emission tomography (PET) studies of the cerebral metabolic rate of oxygen (CMRO2) were performed in seven consecutive patients with bilateral paramedian thalamic infarcts (BPTI), selected on neuroradiological and clinical criteria. The latter consisted of sudden onset of coma or confusion followed by a persistent amnesia of varying severity, with or without language impairment and frontal lobe signs. There was a highly significant decrease of CMRO2 for the whole cortex as well as for all the regions analysed: medial-frontal, latero-frontal, temporal, sensorimotor and posterior associative cortex. The mean regional metabolic ratios (region/whole cortex CMRO2) were not significantly different from controls, indicating an essentially uniform effect in the cortex, except the sensorimotor ratio which was significantly increased. Diffuse cortical hypometabolism most likely reflects thalamo-cortical deafferentation secondary to damage to the 'non-specific' thalamic nuclei, while sparing of the latero-ventral thalamus presumably explains the relative preservation of the sensorimotor cortex metabolism. Although no clear-cut individual relationship was found between magnitude of cortical hypometabolism and the severity and pattern of neuropsychological impairment, the data suggest that the former underlies and/or reflects the latter. Further studies with higher resolution PET devices might shed more light on the relationships between distinct cognitive patterns and specific topography of cortical hypometabolism in BPTI patients.


Subject(s)
Energy Metabolism , Infarction/metabolism , Thalamus/blood supply , Tomography, Emission-Computed , Adult , Aged , Cerebral Cortex/metabolism , Humans , Infarction/diagnostic imaging , Infarction/psychology , Male , Middle Aged , Neuropsychological Tests , Thalamus/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...